Sullivan MA, et al. - Researchers undertook this open-label trial to assess the outcomes of patients with opioid use disorder treated with long-acting injection naltrexone (XR-naltrexone) vs oral naltrexone, both in combination with behavioral therapy. Upon stratification by opioid use severity (≤ 6 bags vs > 6 bags of heroin per day), they randomized (1:1) 60 opioid-dependent adults who completed inpatient opioid withdrawal and were transitioned to oral naltrexone to continue treatment with oral naltrexone (n=32) or XR-naltrexone (n=28) for 24 weeks. Treatment retention was double among patients receiving XR-naltrexone at 6 months vs those taking oral naltrexone. Results thus supported that, for patients seeking opioid withdrawal and nonagonist treatment for preventing relapse to opioid use disorder, XR-naltrexone in combination with behavioral therapy may be an effective treatment.